Emergence of silent NDM-1 carbapenemase gene in carbapenem-susceptible Klebsiella pneumoniae: Clinical implications and epidemiological insights

IF 15.8 1区 医学 Q1 PHARMACOLOGY & PHARMACY Drug Resistance Updates Pub Date : 2024-07-29 DOI:10.1016/j.drup.2024.101123
Juanxiu Qin , Yuan Zhu , Yiwei Zhu , Qianqian Gao , Haomin Zhang , Min Li , Zhen Shen
{"title":"Emergence of silent NDM-1 carbapenemase gene in carbapenem-susceptible Klebsiella pneumoniae: Clinical implications and epidemiological insights","authors":"Juanxiu Qin ,&nbsp;Yuan Zhu ,&nbsp;Yiwei Zhu ,&nbsp;Qianqian Gao ,&nbsp;Haomin Zhang ,&nbsp;Min Li ,&nbsp;Zhen Shen","doi":"10.1016/j.drup.2024.101123","DOIUrl":null,"url":null,"abstract":"<div><p>The global dissemination of carbapenemase genes, particularly <em>bla</em><sub>NDM-1</sub>, poses a significant threat to public health. While research has mainly focused on strains with phenotypic resistance, the impact of silent resistance genes has been largely overlooked. This study documents the first instance of silent <em>bla</em><sub>NDM-1</sub> in a cluster of clonally related carbapenem-susceptible <em>K. pneumoniae</em> strains from a single patient. Despite initial effectiveness of carbapenem therapy, the patient experienced four recurrent lung infections over five months, indicating persistent <em>K. pneumoniae</em> infection. Genomic sequencing revealed all strains harbored <em>bla</em><sub>NDM-1</sub> on the epidemic IncX3 plasmid. A deletion within the upstream promoter region (P<sub>IS<em>Aba125</em></sub>) of <em>bla</em><sub>NDM-1</sub> hindered its expression, resulting in phenotypic susceptibility to carbapenems. However, in vitro bactericidal assays and a mouse infection model showed that <em>K. pneumoniae</em> strains with silent <em>bla</em><sub>NDM-1</sub> exhibited significant tolerance to carbapenem-mediated killing. These findings demonstrate that silent <em>bla</em><sub>NDM-1</sub> can mediate both phenotypic susceptibility and antibiotic tolerance. In silico analysis of 1986 <em>bla</em><sub>NDM</sub> sequences showed that 1956 (98.5%) retained the original promoter P<sub>IS<em>Aba125</em></sub>. Given that previous genomic sequencing typically targets carbapenem-resistant strains, accurately assessing the prevalence of silent <em>bla</em><sub>NDM</sub> remains challenging. This study highlights the hidden threat of silent resistance genes to clinical antimicrobial therapy and calls for enhanced clinical awareness and laboratory detection.</p></div>","PeriodicalId":51022,"journal":{"name":"Drug Resistance Updates","volume":"76 ","pages":"Article 101123"},"PeriodicalIF":15.8000,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Resistance Updates","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1368764624000815","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

The global dissemination of carbapenemase genes, particularly blaNDM-1, poses a significant threat to public health. While research has mainly focused on strains with phenotypic resistance, the impact of silent resistance genes has been largely overlooked. This study documents the first instance of silent blaNDM-1 in a cluster of clonally related carbapenem-susceptible K. pneumoniae strains from a single patient. Despite initial effectiveness of carbapenem therapy, the patient experienced four recurrent lung infections over five months, indicating persistent K. pneumoniae infection. Genomic sequencing revealed all strains harbored blaNDM-1 on the epidemic IncX3 plasmid. A deletion within the upstream promoter region (PISAba125) of blaNDM-1 hindered its expression, resulting in phenotypic susceptibility to carbapenems. However, in vitro bactericidal assays and a mouse infection model showed that K. pneumoniae strains with silent blaNDM-1 exhibited significant tolerance to carbapenem-mediated killing. These findings demonstrate that silent blaNDM-1 can mediate both phenotypic susceptibility and antibiotic tolerance. In silico analysis of 1986 blaNDM sequences showed that 1956 (98.5%) retained the original promoter PISAba125. Given that previous genomic sequencing typically targets carbapenem-resistant strains, accurately assessing the prevalence of silent blaNDM remains challenging. This study highlights the hidden threat of silent resistance genes to clinical antimicrobial therapy and calls for enhanced clinical awareness and laboratory detection.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
碳青霉烯类易感肺炎克雷伯菌中出现沉默的 NDM-1 碳青霉烯酶基因:临床意义和流行病学见解。
碳青霉烯酶基因(尤其是 blaNDM-1)在全球的传播对公共卫生构成了重大威胁。虽然研究主要集中在具有表型耐药性的菌株上,但沉默耐药基因的影响在很大程度上被忽视了。本研究首次记录了来自一名患者的一组克隆相关的碳青霉烯类耐药肺炎克氏菌中的沉默blaNDM-1基因。尽管碳青霉烯类疗法最初有效,但该患者在五个月内经历了四次复发性肺部感染,表明肺炎克氏菌感染持续存在。基因组测序显示,所有菌株都在流行病 IncX3 质粒上携带 blaNDM-1。blaNDM-1 上游启动子区域(PISAba125)的缺失阻碍了其表达,导致表型上对碳青霉烯类敏感。然而,体外杀菌试验和小鼠感染模型表明,具有沉默 blaNDM-1 的肺炎克雷伯菌株对碳青霉烯类药物介导的杀灭表现出明显的耐受性。这些发现表明,沉默的 blaNDM-1 可介导表型易感性和抗生素耐受性。对 1986 个 blaNDM 序列的硅分析表明,1956 个(98.5%)序列保留了原始启动子 PISAba125。鉴于以前的基因组测序通常以耐碳青霉烯菌株为目标,因此准确评估沉默 blaNDM 的流行率仍具有挑战性。这项研究强调了沉默耐药基因对临床抗菌治疗的隐性威胁,并呼吁加强临床意识和实验室检测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Drug Resistance Updates
Drug Resistance Updates 医学-药学
CiteScore
26.20
自引率
11.90%
发文量
32
审稿时长
29 days
期刊介绍: Drug Resistance Updates serves as a platform for publishing original research, commentary, and expert reviews on significant advancements in drug resistance related to infectious diseases and cancer. It encompasses diverse disciplines such as molecular biology, biochemistry, cell biology, pharmacology, microbiology, preclinical therapeutics, oncology, and clinical medicine. The journal addresses both basic research and clinical aspects of drug resistance, providing insights into novel drugs and strategies to overcome resistance. Original research articles are welcomed, and review articles are authored by leaders in the field by invitation. Articles are written by leaders in the field, in response to an invitation from the Editors, and are peer-reviewed prior to publication. Articles are clear, readable, and up-to-date, suitable for a multidisciplinary readership and include schematic diagrams and other illustrations conveying the major points of the article. The goal is to highlight recent areas of growth and put them in perspective. *Expert reviews in clinical and basic drug resistance research in oncology and infectious disease *Describes emerging technologies and therapies, particularly those that overcome drug resistance *Emphasises common themes in microbial and cancer research
期刊最新文献
AI-driven visualization tool for analyzing data and predicting drug-resistant outbreaks. Modeling the epidemiologic impact of age-targeted vaccination for drug-resistant tuberculosis Zebrafish patient-derived xenograft system for predicting carboplatin resistance and metastasis of ovarian cancer. TMOD3 accelerated resistance to immunotherapy in KRAS-mutated pancreatic cancer through promoting autophagy-dependent degradation of ASCL4 Editorial Board
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1